Don S. Urquhart

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial

Félix Ratjen, Christopher Hug, Gautham Marigowda et al. · The Lancet Respiratory Medicine · 2017 · 291 citations

Pulmonary Fibrosis, Medicine, Placebo-controlled Phase 3

Statement on Exercise Testing in Cystic Fibrosis

Helge Hebestreit, Hubertus G.M. Arets, Paul Aurora et al. · Respiration · 2015 · 162 citations · Full text

Physical Activity, Kinesiology, Exercise +8

Cardiopulmonary Exercise Testing Provides Additional Prognostic Information in Cystic Fibrosis

Helge Hebestreit, Erik H.J. Hulzebos, Jane E. Schneiderman et al. · American Journal of Respiratory and Critical Care Medicine · 2018 · 139 citations · Full text

Effects of a Partially Supervised Conditioning Program in Cystic Fibrosis: An International Multicenter, Randomized Controlled Trial (ACTIVATE-CF)

Helge Hebestreit, Susi Kriemler, Christian Schindler et al. · American Journal of Respiratory and Critical Care Medicine · 2021 · 56 citations · Full text

Central sleep-disordered breathing and the effects of oxygen therapy in infants with Prader-Willi syndrome

Don S. Urquhart, Tanya Gulliver, G. Williams et al. · Archives of Disease in Childhood · 2013 · 55 citations